Wide-spectrum characterization of trabectedin: Biology, clinical activity and future perspectives

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 865-878

  Vincenzi, Bruno ^a   Napolitano, Andrea ^a   Frezza, Anna Maria ^a   Schiavon, Gaia ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Adducts; Cancer; Double strand breaks; ET 743; MDR1; NER; Ovarian; Sarcomas; Therapy; Trabectedin

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; DNA DIRECTED DNA POLYMERASE ALPHA; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR FACTOR Y; PACLITAXEL; TRABECTEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SXR; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; DNA ADDUCT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTINUOUS INFUSION; CYTOTOXICITY TEST; DNA ADDUCT; DNA ALKYLATION; DNA REPAIR; DNA SEQUENCE; DNA STRAND BREAKAGE; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSFORMATION; GENE EXPRESSION; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MYXOSARCOMA; NEUTROPENIA; NONHUMAN; PHARMACOLOGICAL BLOCKING; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOCYTOPENIA; ANIMAL; CELL CYCLE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASMS; UROCHORDATA;

ECTEINASCIDIA TURBINATA;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; CLINICAL TRIALS AS TOPIC; DIOXOLES; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; TETRAHYDROISOQUINOLINES; UROCHORDATA;

EID: 77952921894     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.69     Document Type: Review

References (142)

1. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH: Marine natural products as anticancer drugs. Mol. Cancer Ther. 4(2), 333-342 (2005).
2. Food-Drugs From The Sea (Proceedings of the Food-Drugs from the Sea Symposium). Kingston, RI, USA, 24-27 August, 1969). Youngken HW Jr (Ed.). Marine Technology Society, Washington, DC, USA (1970).
3. Rinehart KL: Antitumor compounds from tunicates. Med. Res. Rev. 20(1), 1-27 (2000).
4. Corey EJ, Gin DY, Kania RS: Enantioselective total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 118(38), 9202-9203 (1996).
5. Cuevas C, Frascesch A: Development of Yondelis® (trabectedin, ET-743) A semisyntetic process solves the supply problem. Nat. Prod. Rep. 26, 322-337 (2009).
6. Ikeda Y, Idemoto H, Hirayama F et al.: Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation. J. Antibiot. 36, 1279-1283 (1983).
7. Menchaca R, Martinez V, Rodriguez A et al.: Synthesis of natural ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from cyanosafracin B. J. Org. Chem. 68(23), 8859-8866 (2003).
8. Chen J, Chen X, Bois-Choussy M, Zhu J: Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 128, 87-89 (2006).
9. Saito N, Tachi M, Seki R, Kamayachi H, Kubo A: A practical synthesis of the ABC ring model of ecteinascidins. A. Chem. Pharm. Bull. 48, 1549-1557 (2000).
10. Zhou B, Guo J, Danishefsky SJ: Studies directed to the total synthesis of ET 743 and analogues thereof: an expeditious route to the ABFGH subunit. Org. Lett. 4, 43-46 (2002).
11. Jin W, Metobo S, Williams RM: Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins. Org. Lett. 5, 2095-2098 (2003).
12. Magnus P, Matthews KS, Lynch V: New strategy for the synthesis of tetrahydroisoquinoline alkaloids. Org. Lett. 5, 2181-2184 (2003).
13. Chen X, Chen J, De Paolis M, Zhu J: Synthetic Studies toward ecteinascidin 743. J. Org. Chem. 70, 4397-4408 (2005).
14. Zheng S, Chan C, Furuuchi T et al.: Stereospecifc formal total synthesis of ecteinascidin 743. Angew. Chem. Int. Ed. Engl. 45, 1754-1759 (2006).
15. Fishlock D, Williams RM: Synthetic studies on ET-743. Asymmetric, stereocontrolled construction of the tetrahydroisoquinoline core via radical cyclization on a glyoxalimine. Org. Lett. 8(15), 3299-3301 (2006).
16. Fishlock D, Williams RM. Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis. J. Org. Chem. 73(24), 9594-9600 (2008).
17. Marco E, David-Cordonnier MH, Bailly C, Cuevas C, Gago F: Further insight into the DNA recognition mechanism of trabectedin from the differential affnity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J. Med. Chem. 49(23), 6925-6929 (2006).
18. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 66, 8155-8162 (2006).
19. David-Cordonnier MH, Gajate C, Olmea O et al.: DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem. Biol. 12(11), 1201-1210 (2005).
20. Erba E, Cavallaro E, Damia G et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol. Res. 14(11-12), 579-587 (2004).
21. Guan Y, Sakai R, Rinehart KL, Wang AH: Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J. Biomol. Struct. Dyn. 10(5), 793-818 (1993).
22. Sakai R, Rinehart KL, Guan Y, Wang AH: Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc. Natl Acad. Sci. USA 89(23), 11456-11460 (1992).
23. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35(41), 13303-13309 (1996).
24. Seaman FC, Hurley L: Interstrand cross-linking by bizelesin produces a Watson-Crick to Hoogsteen base-pairing transition region in d(CGTAATTACG)2. Biochemistry 32(47), 12577-12585 (1993).
25. Zewail-Foote M, Hurley LH: Ecteinascidin-743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42(14), 2493-2497 (1999).
26. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME: Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl Acad. Sci. USA 92(19), 8861-8865 (1995).
27. Zewail-Foote M, Hurley LH: Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc. 123(27), 6485-6495 (2001).
28. Takebayashi Y, Poourquier P, Yoshida A, Kohlhagen G, Pommier Y: Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl Acad. Sci. USA 96, 7196-7201 (1999)
29. Pommier Y, Pourquier P, Fan Y, Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400(1-3), 83-105 (1998).
30. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y: Ecteinascidin-743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res. 7(1),185-191 (2001).
31. Erba E, Bergamaschi D, Bassano L et al.: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37(1), 97-105 (2001).
32. Bonfanti M, La Valle E, Fernandez Sousa Faro JM et al.: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 14(3), 179-186 (1999).
33. García-Nieto R, Manzanares I, Cuevas C, Gago F: Increased DNA binding specifcity for antitumor ecteinascidin 743 through protein-DNA interactions? J. Med. Chem. 43(23), 4367-4369 (2000).
34. Marco E, García-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F: A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc fnger-induced DNA structural distortions. J. Med. Chem. 45(4), 871-880 (2002).
35. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl Acad. Sci. USA 97(12), 6780-6784 (2000).
36. Jin S, Gorfajn B, Faircloth G, Scotto KW: Ecteinascidin-743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl Acad. Sci. USA 97(12), 6775-6779 (2000).
37. Kanzaki A, Takebayashi Y, Ren XQ et al.: Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol. Cancer Ther. 1(14), 1327-1334 (2002).
38. Erba E, Bergamaschi D, Bassano L et al.: Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br. J. Cancer. 82(10), 1732-1739 (2000).
39. Louneva N, Saitta B, Herrick DJ, Jimenez SA: Transcriptional inhibition of type I collagen gene expression in scleroderma fbroblasts by the antineoplastic drug ecteinascidin 743. J. Biol. Chem. 278(41), 40400-40407 (2003).
40. Shao L, Kasanov J, Hornicek FJ, Morii T, Fondren G, Weissbach L: Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem. Pharmacol. 66(12), 2381-2395 (2003).
41. Garcia-Rochal M, Garcia-Gravalos MD, Avila J: Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br. J. Cancer 73(8), 875-883 (1996).
42. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW: Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 62(12), 3377-3381 (2002).
43. Synold TW, Dussault I, Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and effux. Nat. Med. 7(5), 584-590 (2001).
44. Xie W, Barwick JL, Downes M et al.: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406(6794), 435-439 (2000).
45. Martinez EJ, Corey EJ, Owa T: Antitumor activity-and gene expression-based profling of ecteinascidin ET 743 and phthalascidin PT 650. Chem. Biol. 8(12), 1151-1160 (2001).
46. Marchini S, Marrazzo E, Bonomi R et al.: Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur. J. Cancer. 41(2), 323-333 (2005).
47. Minuzzo M, Ceribelli M, Pitarque-Martì M et al.: Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol. Pharmacol. 68(5), 1496-1503 (2005).
48. Gajate C, An F, Mollinedo F: Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J. Biol. Chem. 277(44), 41580-41589 (2002).
49. Takebayashi Y, Pourquier P, Zimonjic DB, et al.: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7(8), 961-966 (2001).
50. Damia G, Silvestri S, Filiberti L, Broggini M, D'Incalci M: Importance of DNA repair mechanisms for the sensitivity of tumor cells to ET-743. Proceedings of the 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Washington DC, USA, 16-19 November 1999 (Abstract 3872).
51. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH: The ineffciency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8(11), 1033-1049 (2001).
52. Damia G, Silvestri S, Carrassa L et al.: Unique pattern of ET-743 activity in different cellular systems with defned defciencies in DNA-repair pathways. Int. J. Cancer 92, 583-588 (2001).
53. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M: Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-defcient and NER-profcient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 40, 885-904 (2007).
54. Aune GJ, Takagi K, Sordet O et al.: Von Hippel-Lindau coupled and transcription-coupled nucleotide excision repair dependent degradation of RNA polymerase II in response to trabectedin. Clin. Cancer Res. 14(20), 6449-6455 (2008)
55. Grazziotin Soares D, Escargueil AE, Poindessous V et al.: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104(32), 13062-13067 (2007).
56. Guirouilh-Barbat J, Redon C, Pommier Y: Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol. Biol. Cell. 19(9), 3969-3981 (2008).
57. Tavecchio M, Simone M, Erba E et al.: Role of homologous recombination in trabectedin-induced DNA damage. Eur. J. Cancer 44(4), 609-618 (2008).
58. Marco E, Gago F: DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands. Mol. Pharmacol. 68, 1559-1567 (2005).
59. Casado JA, Río P, Marco E et al.: Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol. Cancer Ther. 7(5), 1309-1318 (2008).
60. Andreassen PR, Ho GP, D'Andrea AD: DNA damage responses and their many interactions with the replication fork. Carcinogenesis 27, 883-892 (2006).
61. Sparidans RW, Rosing H, Hillebrand MJX et al.: Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs 12, 653-666 (2001).
62. Beumer JH, Rademaker-Lakhai JM, Rosing H et al.: Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother. Pharmacol. 59, 825-837 (2007).
63. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH: Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest. New Drugs 23(5), 429-436 (2005).
64. Reid JM, Kuffel MJ, Ruben SL et al.: Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res. 8, 2952-2962 (2002).
65. Brandon EFA, Meijerman I, Klijn JS et al.: In-vitro cytotoxicity of ET-743 (trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: infuence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 16, 935-943 (2005).
66. Brandon EFA, Sparidans RW, Guijt K et al.: In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, trabectedin), a novel marine anticancer drug. Invest. New Drugs 24, 3-14 (2006).
67. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M: Metabolic Drug Interactions. Lippincott Williams and Wilkins, PA, USA (2000).
68. Mirsalis JC, Schindler-Horvat JE, Tomaszewski JE et al.: Preclinical toxicology studies of ecteinascidin 743. Proc. Am. Assoc. Cancer Res. 37, 375 (1996).
69. Mirsalis JC, Fairchild DG, Smith S et al.: Toxicity of ecteinascidin 743 in female Fischer-344 rats administered i.v. in a multiple-dose regimen. Proc. Am. Assoc. Cancer Res. 38, 309 (1997).
70. Donald S, Verschoyle RD, Edwards R et al.: Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res. 62(15), 4256-4262 (2002).
71. Valoti G, Nicoletti MI, Pellegrino A et al.: Ecteinascidin-743, a new marine product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4, 1977-1983 (1998)
72. Donald S, Verschoyle RD, Greaves P et al.: Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res. 63, 5902-5908 (2003).
73. Hari P, Srivastava RN: Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Ind. J. Pediatr. 65, 557-560 (1998).
74. Sprung CL, Caralis PV, Marcial EH et al.: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med. 311, 1137-1143 (1984).
75. Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, Williams DE: Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3-diindolylmethane in Sprague-Dawley rats. Toxicol. Sci. 74, 10-21 (2003).
76. Donald S, Verschoyle RD, Greaves P et al.: Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectedin) without compromising effcacy in a rat mammary carcinoma. Int. J. Cancer 111(6), 961-967 (2004).
77. Donald S, Verschoyle RD, Greaves P, Orr S, Jimeno J, Gescher AJ: Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother. Pharmacol. 53, 305-312 (2004).
78. Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL: Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance- associated proteins (MRPs) may prevent hepatotoxicity. Toxicol. Appl. Pharmacol. 228(1), 17-23 (2008).
79. Perez-Ruizo JJ, Zannikos P, Hirankarn S et al.: Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin. Pharmacokinet. 46(10), 867-884 (2007).
80. Fetterly GJ, Owen JS, Stuyckens K et al.: Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother. Pharmacol. 62(1), 135-147 (2008).
81. Villalona-Calero MA, Eckhardt SG, Weiss G et al.: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin. Cancer Res. 8(1), 75-85 (2002).
82. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P: Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin. Pharmacol. Ther. 83(1), 130-143 (2008).
83. Gómez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B: In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp. Hematol. 31(11), 1104-1111 (2003).
84. Allavena P, Signorelli M, Chieppa M et al.: Anti-infammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65(7), 2964-2971 (2005).
85. Grosso F, Dileo P, Sanflippo R et al.: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer 42(10), 1484-1490 (2006).
86. Ryan DP, Supko JG, Eder JP et al.: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res. 7, 231-242 (2001)
87. Brain EG: Safety and effcacy of ET-743: The French experience. Anticancer Drugs 13, S11-S14 (2002).
88. Yovine A, Riofrio M, Blay JY et al.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22, 890-899 (2004).
89. Gomez J, Lopez Lazaro L, Guzman C et al.: Identifcation of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Presented at: 2000 ASCO Annual Meeting. New Orleans, LA, USA, 20-23 May (2000).
90. Skorupa A, Beldner M, Kraft A, Montero AJ: Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol. Ther. 6(7), 1015-1017 (2007).
91. Theman TA, Hartzell TL, Sinha I et al.: Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J. Clin. Oncol. 27(33), E198-E200 (2009).
92. Izbicka E, Lawrence R, Raymond E et al.: In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 9(9), 981-987 (1998).
93. Valoti G, Nicoletti MI, Pellegrino A et al.: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4(8), 1977-1983 (1998).
94. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT: High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 10(10), 1233-1240 (1999).
95. Martinez N, Sanchez-Beato M, Carnero A et al.: Transcriptional signature of Ecteinascidin-743 (Yondelis, trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol. Cancer Ther. 4(5), 814-823 (2005).
96. Forni C, Minuzzo M, Virdis E et al.: Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8(2), 449-457 (2009).
97. Takahashi N, Li W, Banerjee D et al.: Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 62(23), 6909-6915 (2002).
98. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res. 7(10), 3251-3257 (2001).
99. D'Incalci M, Colombo T, Ubezio P et al.: The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur. J. Cancer 39(13), 1920-1926 (2003).
100. Riccardi A, Meco D, Ubezio P et al.: Combination of trabectedin and irinotecan is highly effectivein a human rhabdomyosarcoma xenograft. Anticancer Drugs 16, 811-815 (2005).
101. Meco D, Colombo T, Ubezio P et al.: Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother. Pharmacol. 52(2), 131-138 (2003).
102. Scotlandi K, Perdichizzi S, Manara MC et al.: Effectiveness of ecteinascidin-743 against drug-sensitive and-resistant bone tumor cells. Clin. Cancer Res. 8(12), 3893-3903 (2002).
103. Morioka H, Weissbach L, Vogel T et al.: Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin. Cancer Res. 9(3), 1211-1217 (2003).
104. Simoens C, Korst AE, De Pooter CM et al.: In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br. J. Cancer 89(12), 2305-2311 (2003).
105. Romero J, Zapata I, Córdoba S et al.: In vitro radiosensitisation by trabectedin in human cancer cell lines. Eur. J. Cancer 44(12), 1726-1733 (2008).
106. Beumer JH, Buckle T, Ouwehand M et al.: Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest. New Drugs 25(1), 1-7 (2007).
107. Manara MC, Perdichizzi S, Serra M et al.: The molecular mechanisms responsible for resistance to ET-743 (trabectedin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int. J. Oncol. 27(6), 1605-1616 (2005).
108. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother. Pharmacol. 63(6), 1121-1129 (2009).
109. Moneo V, Serelde BG, Fominaya J et al.: Extreme sensitivity to Yondelis (trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J. Cell. Biochem. 100(2), 339-348 (2007).
110. Zhan M, Yu D, Lang A, Li L, Pollock RE: Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug reisistance-1 expression. Cancer. 92, 1556-1566 (2001).
111. Duan Z, Choy E, Harmon D et al.: ZNF93 increases resistance to ET-743 (trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS One 4(9), E6967 (2009).
112. van Kesteren C, Cvitkovic E, Taamma A et al.: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a Phase I dose-fnding study. Clin. Cancer Res. 6(12), 4725-4732 (2000).
113. Taamma A, Misset JL, Riofrio M et al.: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19, 1256-1265 (2001).
114. Puchalski TA, Ryan DP, Garcia-Carbonero R et al.: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother. Pharmacol. 50(4), 309-319 (2002).
115. van Kesteren C, Twelves C, Bowman A et al.: Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin-743 administered as a 1-and 3-h infusion in a Phase I study. Anticancer Drugs 13(4), 381-393 (2002).
116. Lau L, Supko JC, Blaney S et al.: A Phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. a children's oncology group study. Clin. Cancer Res. 11(2 Pt 1), 672-677 (2005). (Pubitemid 40116894)
117. Forouzesh B, Hidalgo M, Chu Q et al.: Phase I and pharmacokinetic study of trabectedin as a 1-or 3-hour infusion weekly in patients with advanced solid malignancies. Clin. Cancer Res. 15(10), 3591-3599 (2009).
118. von Mehren M, Schilder RJ, Cheng JD et al.: A Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann. Oncol. 19(10), 1802-1809 (2008).
119. Messersmith WA, Jimeno A, Ettinger D et al.: Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63, 181-188 (2008).
120. Blay JY, von Mehren M, Samuels BL et al.: Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin. Cancer Res. 14(20), 6656-6662 (2008).
121. Sessa C, Cresta S, Noberasco C et al.: Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur. J. Cancer 45(12), 2116-2122 (2009).
122. Sessa C, Perotti A, Noberasco C et al.: Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer 45(7), 1153-1161 (2009).
123. Huygh G, Clement PM, Dumez H et al.: Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006, 56282 (2006).
124. Grosso F, Jones RL, Demetri GD et al.: Effcacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
125. Grosso F, Sanflippo R, Virdis E et al.: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann. Oncol. 20(8), Phase I9-44 (2009).
126. Tewari D, Saffari B, Cowan C, Wallick AC, Koontz MZ, Monk BJ: Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma. Gynecol. Oncol. 102(3), 421-424 (2006).
127. Hollebecque A, Adenis A, Taieb S, Lebedinsky C, Penel N: Inadequacy of size-based response criteria to assess the effcacy of trabectedin among metastatic sarcoma patients. Invest. New Drugs DOI: 10.1007/s10637-009-9262-4 (2009) (Epub ahead of print).
128. Delaloge S, Yovine A, Taamma A et al.: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol. 19(5), 1248-1255 (2001).
129. Garcia-Carbonero R, Supko JG, Manola J et al.: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22(8), 1480-1490 (2004).
130. Le Cesne A, Blay JY, Judson I et al.: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005).
131. Garcia-Carbonero R, Supko JG, Maki RG et al.: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484-5492 (2005).
132. Demetri GD, Chawla SP, von Mehren M et al.: Effcacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase ii study of two different schedules. J. Clin. Oncol. 27(25), 4188-4196 (2009).
133. Roylance R, Seddon B, McTiernan A, Sykes K, Daniels S, Whelan J: Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Clin. Oncol. (R. Coll. Radiol.) 19(8), 572-576 (2007).
134. Sessa C, De Braud F, Perotti A et al.: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23(9),1867-1874 (2005).
135. Krasner CN, McMeekin DS, Chan S et al.: A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97(12), 1618-1624 (2007).
136. Del Campo JM, Roszak A, Bidzinski M et al.: Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 20(11), 1794-1802 (2009).
137. McMeekin DS, Lisyanskaya A, Crispens M et al.: Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter Phase II study. Gynecol. Oncol. 114(2), 288-292 (2009).
138. Zelek L, Yovine A, Brain E et al.: A Phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br. J. Cancer 94(11), 1610-1614 (2006).
139. Ryan DP, Puchalski T, Supko JG et al.: A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 7(6), 531-538 (2002).
140. Blay J Y, Le Cesne A, Verweij J et al.: A Phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 40(9), 1327-1331 (2004).
141. Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E et al.: Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. Clin. Colorectal Cancer 6(7), 522-528 (2007).
142. Stevens EV, Nishizuka S, Antony S et al.: Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol. Cancer Ther. 7(1), 10-18 (2008).